A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites

Infection and Immunity

Volumn 75, Issue 3, 2007, Pages 1177-1185

  Yadava, Anjali ^a   Sattabongkot, Jetsumon ^b   Washington, Michael A ^a   Ware, Lisa A ^a   Majam, Victoria ^c   Zheng, Hong ^c   Kumar, Sanjai ^c   Ockenhouse, Christian F ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; PLASMODIUM VIVAX PROTEIN 1; UNCLASSIFIED DRUG; VMP 001;

ADOLESCENT; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; DRUG PROTEIN BINDING; ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; QUALITY OF LIFE; SPOROZOITE;

ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; MALARIA VACCINES; MALARIA, VIVAX; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; SPOROZOITES; VACCINES, SUBUNIT;

EID: 33847754745     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01667-06     Document Type: Article

References (54)

1. Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, P. Aide, B. Sigauque, J. Milman, I. Mandomando, Q. Bassat, C. Guinovart, M. Espasa, S. Corachan, M. Lievens, M. M. Navia, M. C. Dubois, C. Menendez, F. Dubovsky, J. Cohen, R. Thompson, and W. R. Ballou. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up o f a randomised controlled trial. Lancet 366:2012-2018.
2. Arevalo-Herrera, M., and S. Herrera. 2001. Plasmodium vivax malaria vaccine development. Mol. Immunol. 38:443-455.
3. Arevalo-Herrera, M., M. A. Roggero, J. M. Gonzalez, J. Vergara, G. Corradin, J. A. Lopez, and S. Herrera. 1998. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aolus monkeys. Ann. Trop. Med. Parasitol. 92:539-551.
4. + T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol. 24:161-169.
5. Arnot, D. E., J. W. Barnwell, J. P. Tam, V. Nussenzweig, R. S. Nussenzweig, and V. Enea. 1985. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230: 815-818.
6. Barr, P. J., H. L. Gibson, V. Enea, D. E. Arnot, M. R. Hollingdale, and V. Nussenzweig. 1987. Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J. Exp. Med. 165:1160-1171.
7. Bilsborough, J., K. Baumgart, I. Bathurst, P. Barr, and M. F. Good. 1997. Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites. Acta Trop. 65:59-80.
8. Cerami, C., U. Frevert, P. Sinnis, B. Takacs, P. Clavijo, M. J. Santos, and V. Nussenzweig. 1992. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70:1021-1033.
9. Chappel, J. A., W. O. Rogers, S. L. Hoffman, and A. S. Kang. 2004. Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malaria J. 29:3-28.
10. Chappel, J. A., M. R. Hollingdale, and A. S. Kang. 2004. IgG(4) Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes. Hum. Antibodies 13:91-96.
11. Charoenvit, Y., W. E. Collins, T. R. Jones, P. Millet, L. Yuan, G. H. Campbell, R. L. Beaudoin, J. R. Broderson, and S. L. Hoffman. 1991. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251:668-671.
12. Chatterjee, S., M. Wery, P. Sharma, and V. S. Chauhan. 1995. A conserved peptide sequence of the Plasmodium falciparum Circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Infect. Immun. 63:4375-4381.
13. Clyde, D. F. 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24:397-401.
14. Cochrane, A. H., J. W. Barnwell, W. E. Collins, and R. S. Nussenzweig. 1985. Monoclonal antibodies produced against sporozoites of the human parasite Plasmodium malariae abolish infectivity of sporozoites of the simian parasite Plasmodium brasilianum. Infect. Immun. 50:58-61.
15. Collins, W. E., R. S. Nussenzweig, W. R. Ballou, T. K. Ruebush II, E. H. Nardin, J. D. Chulay, W. R. Majarian, J. F. Young, G. F. Wasserman, I. Bathurst, H. L. Gibson, P. J. Barr, S. L. Hoffman, S. S. Wasserman, J. R. Broderson, J. C. Skinner, P. M. Procell, V. R. Filipski, and C. L. Wilson. 1989. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am. J. Trop. Med. Hyg. 40:455-464.
16. Doolan, D. L., and S. L. Hoffman. 2000. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165:1453-1462.
17. Franke, E. D., C. M. Lucas, E. San Roman, and R. A. Wirtz. 1992. Prevalence of antibody to the variant repeat of the Circumsporozoite protein of Plasmodium vivax in Peru. Am. J. Trop. Med. Hyg. 46:708-710.
18. Good, M. F. 2005. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends Immunol. 26:295-297.
19. Gordon, D. M., T. M. Cosgriff, I. Schneider, G. F. Wasserman, W. R. Majarian, M. R. Hollingdale, and J. D. Chulay. 1990. Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine. Am. J. Trop. Med. Hyg. 42:527-531.
20. Guerra, C. A., R. W. Snow, and S. I. Hay. 2006. Mapping the global extent of malaria in 2005. Trends Parasitol. 22:353-358.
21. Heppner, D. G., Jr., K. E. Kester, C. F. Ockenhouse, N. Tornieporth, O. Ofori, J. A. Lyon, V. A. Stewart, P. Dubois, D. E. Lanar, U. Krzych, P. Moris, E. Angov, J. F. Cummings, A. Leach, B. T. Hall, S. Dutta, R. Schwenk, C. Hillier, A. Barbosa, L. A. Ware, L. Nair, C. A. Darko, M. R. Withers, B. Ogutu, M. E. Polhemus, M. Fukuda, S. Pichyangkul, M. Gettyacamin, C. Diggs, L. Soisson, J. Milman, M. C. Dubois, N. Garcon, K. Tucker, J. Wittes, C. V. Plowe, M. A. Thera, O. K. Duombo, M. G. Pau, J. Goudsmit, W. R. Ballou, and J. Cohen. 2005. Towards an RTS.S-based, multi-stage, multiantigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23:2243-2250.
22. Herrera, S., A. Bonelo, B. L. Perlaza, O. L. Fernandez, L. Victoria, A. M. Lenis, L. Soto, H. Hurtado, L. M. Acuna, J. D. Velez, R. Palacios, M. Chen-Mok, G. Corradin, and M. Arevalo-Herrera. 2005. Safety and elicitation of humoral and cellular responses in Colombian malaria-naive volunteers by a Plasmodium vivax Circumsporozoite protein-derived synthetic vaccine. Am. J. Trop. Med. Hyg. 73:3-9.
23. Herrera, S., C. De Plata, M. Gonzalez, B. L. Perlaza, F. Bettens, G. Corradin, and M. Arevalo-Herrera. 1997. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing Plasmodium vivax CS epitopes in Aotus monkeys. Parasite Immunol. 19:161-170.
24. Herrington, D. A., E. H. Nardin, G. Losonsky, I. C. Bathurst, P. J. Barr, M. R. Hollingdale, R. Edelman, and M. M. Levine. 1991. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Am. J. Trop. Med. Hyg. 45:695-701.
25. Hoffman, S. L., L. M. Goh, T. C. Luke, I. Schneider, T. P. Le, D. L. Doolan, J. Sacci, P. de la Vega, M. Dowler, C. Paul, D. M. Gordon, J. A. Stoute, L. W. Church, M. Sedegah, D. G. Heppner, W. R. Ballou, and T. L. Richie. 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185:1155-1164.
26. Jones, T. R., L. F. Yuan, H. A. Marwoto, D. M. Gordon, R. A. Wirtz, and S. L. Hoffman. 1992. Low immunogenicity of a Plasmodium vivax Circumsporozoite protein epitope bound by a protective monoclonal antibody. Am. J. Trop. Med. Hyg. 47:837-843.
27. Kappe, S. H., C. A. Buscaglia, and V. Nussenzweig. 2004. Plasmodium sporozoite molecular cell biology. Annu. Rev. Cell Dev. Biol. 20:29-59.
28. Luke, T. C., and S. L. Hoffman. 2003. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206:3803-3808.
29. Mann, V. H., T. Huang, Q. Cheng, and A. Saul. 1994. Sequence variation in the Circumsporozoite protein gene of Plasmodium vivax appears to be regionally biased. Mol. Biochem. Parasitol. 68:45-52.
30. McCutchan, T. F., J. C. Kissinger, M. G. Touray, M. J. Rogers, J. Li, M. Sullivan, E. M. Braga, A. U. Krettli, and L. H. Miller. 1996. Comparison of circumsporozoite proteins from avian and mammalian malarias: biological and phylogenetic implications. Proc. Natl. Acad. Sci. USA 93:11889-11894.
31. McCutchan, T. F., A. A. Lal, V. F. de la Cruz, L. H. Miller, W. L. Maloy, Y. Charoenvit, R. L. Beaudoin, P. Guerry, R. Wistar, Jr., S. L. Hoffman, W. T. Hockmeyer, W. E. Collins, and D. Wirth. 1985. Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science 230:1381-1383.
32. + T-cell response is elicited using the synthetic polypeptide from the C terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine 23:2801-2812.
33. Millet, P., C. Chizzolini, R. A. Wirtz, I. Bathurst, J. R. Broderson, G. H. Campbell, and W. E. Collins. 1992. Inhibitory activity against sporozoites induced by antibodies directed against nonrepetitive regions of the circumsporozoite protein of Plasmodium vivax. Eur. J. Immunol. 22:519-524.
34. Mota, M. M., and A. Rodriguez. 2004. Migration through host cells: the first steps of Plasmodium sporozoites in the mammalian host. Cell Microbiol. 6:1113-1118.
35. Mueller, A. K., M. Labaied, S. H. Kappe, and K. Matuschewski. 2005. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433:164-167.
36. Nardin, E., F. Zavala, V. Nussenzweig, and R. S. Nussenzweig. 1999. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parasitologia 41:397-402.
37. Nardin, E. H., P. J. Barr, E. Heimer, and H. M. Etlinger. 1988. Genetic restriction of the murine humoral response to a recombinant Plasmodium vivax circumsporozoite protein. Eur. J. Immunol. 18:1119-1122.
38. Rathore, D., R. Nagarkatti, D. Jani, R. Chattopadhyay, P. de la Vega, S. Kumar, and T. F. McCutchan. 2005. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J. Biol. Chem. 280:20524-20529.
39. Rathore, D., J. B. Sacci, P. de la Vega, and T. F. McCutchan. 2002. Binding and invasion of liver cells by Plasmodium falciparum sporozoites: essential involvement of the amino terminus of circumsporozoite protein. J. Biol. Chem. 277:7092-7098.
40. Reed, R. C., V. Louis-Wileman, E. V. Cosmai, S. Fang, D. L. Jue, R. M. Wohlhueter, R. L. Hunter, and A. A. Lal. 1997. Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii. Vaccine 15: 482-488.
41. Robert, L. L., P. D. Santos-Ciminera, R. G. Andre, G. W. Schultz, P. G. Lawyer, J. Nigro, P. Masuoka, R. A. Wirtz, J. Neely, D. Gaines, C. E. Cannon, D. Pettit, C. W. Garvey, D. Goodfriend, and D. R. Roberts. 2005. Plasmodium-infected Anopheles mosquitoes collected in Virginia and Maryland following local transmission of Plasmodium vivax malaria in Loudoun County, Virginia. J. Am. Mos. Qcontrol. Assoc. 21:187-193.
42. Rodriguez-Morales, A. J., E. Sanchez, M. Vargas, C. Piccolo, R. Colina, and M. Arria. 2006. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J. Trop. Pediatr. 52:49-51.
43. Rogers, W. O., W. R. Weiss, A. Kumar, J. C. Aguiar, J. A. Tine, R. Gwadz, J. G. Harre, K. Gowda, D. Rathore, S. Kumar, and S. L. Hoffman. 2002. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect. Immun. 70:4329-4335.
44. Sattabongkot, J., N. Yimamnuaychoke, S. Leelaudomlipi, M. Rasameesoraj, R. Jenwithisuk, R. E. Coleman, R. Udomsangpetch, L. Cui, and T. G. Brewer. 2006. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 74:708-715.
45. Schofield, L., and P. Uadia. 1990. Lack of Ir gene control in the immune response to malaria. I. A thymus-independent antibody response to the repetitive surface protein of sporozoites. J. Immunol. 144:2781-2788.
46. Schwenk, R., L. V. Asher, I. Chalom, D. Lanar, P. Sun, K. White, D. Keil, K. E. Kester, J. Stoute, D. G. Heppner, and U. Krzych. 2003. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol. 25:17-25.
47. Shi, Y. P., V. Udhayakumar, M. P. Alpers, M. M. Povoa, A. J. Oloo, T. K. Ruebush II, and A. A. Lal. 1993. Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein. Infect. Immun. 61:2425-2433.
48. Suphavilai, C., S. Looareesuwan, and M. F. Good. 2004. Analysis of circumsporozoite protein-specific immune responses following recent infection with Plasmodium vivax. Am. J. Trop. Med. Hyg. 71:29-39.
49. Udhayakumar, V., A. Saekhou, S. Fang, D. Jue, R. M. Wohlhueter, and A. A. Lal. 1998. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC). Vaccine 16:982-988.
50. Vanderberg, J. P., and U. Frevert. 2004. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34:991-996.
51. Wirtz, R. A., Y. Charoenvit, T. R. Burkot, K. M. Esser, R. L. Beaudoin, W. E. Collins, and R. G. Andre. 1991. Evaluation of monoclonal antibodies against Plasmodium vivax sporozoites for ELISA development. Med. Vet. Entomol. 5:17-22.
52. Yadava, A., and C. F. Ockenhouse. 2003. Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems. Infect. Immun. 71:4961-4969.
53. Ying, P., M. Shakibaei, M. S. Patankar, P. Clavijo, R. C. Beavis, G. F. Clark, and U. Frevert. 1997. The malaria circumsporozoite protein: interaction of the conserved regions I and II-plus with heparin-like oligosaccharides in heparan sulfate. Exp. Parasitol. 85:168-182.
54. Zakeri, S., A. Abouie-Mehrizi, N. D. Djadid, and G. Snounou. 2006. Circumsporozoite protein gene diversity among temperate and tropical Plasmodium vivax isolates from Iran. Trop. Med. Int. Health 11:729-737.